Explore the vast range of titles available.

Sexual health is a critical component of quality of life. Chronic pain can significantly impair sexual functioning through complex and multimodal effects spanning physical, psychological, and social domains. Nevertheless, when properly managed, many people with chronic pain can still enjoy fulfilling sexual relationships. Therefore, addressing sexual health concerns is an important aspect of holistic modern chronic pain management. This study is the first to investigate attitudes and perspectives of pain specialists regarding sexual health issues, including barriers to diagnosis and management. A Nationwide web-based survey of all registered and active board-certified pain specialists in Israel held in August–September 2024. Out of 133 physician members of the Israeli Pain Association, 75 (56.4%) completed the survey, 62.7% of them males, and most (73.3%) worked in public facilities, and the primary specialty of 41.3% was anesthesiology. While 81.3% of physicians acknowledged the high prevalence of sexual dysfunction in chronic pain patients, only 14.7% proactively discuss it with patients. Similarly, 89.3% reported little to no training on sexual health, and 60% felt underprepared to address these issues. Most felt more comfortable discussing sexual health with same-gender patients, time constraints, low priority, and lack of knowledge were noted as key barriers. This study reveals a gap between physicians’ awareness of sexual health issues and their translation of this into clinical practice. Time constraints, discomfort, and insufficient training hinder discussions. Improving referral pathways and fostering system-level support are essential to integrating sexual health into routine pain management. In particular, the results underscore an urgent need to integrate sexual health training into pain medicine, which could improve patient outcomes and quality of life among chronic pain patients.

Background. Chronic pain (CP) prevalence in different studies has been inconsistent, ranging from 12% in Spain to 42% in the UK. Purpose. We conducted an internet-based survey in a representative cohort of Israeli adults assembled by a large professional survey company in order to probe the prevalence of CP in Israel. Methods. 8,300 Israeli adults comprising a representative cohort of the Israeli population were asked whether they were suffering from pain lasting over 3 months. 1647 participants responded (19.8% response rate). Of these, 515 (31.3%) had CP. Participants with CP were then asked a series of follow-up questions regarding their chronic pain. Statistical weights were used to correct for the distribution of the Israeli population based on sociodemographic characteristics. Results. CP patients were significantly older than respondents without pain. The average daily pain was 5.8/10 on a numerical rating scale. Common pain locations were axial skeleton and headaches. However, over half of patients reported pain in multiple body areas, and around a fifth had an undiagnosed chronic pain syndrome. Around 40% of pain patients reported to have visited a specialized pain clinic, and the same proportion has consulted several specialists. Despite this, a sizable proportion of high pain intensity patients were still left with no or inefficient treatment to alleviate their pain. Conclusions. This is the first internet survey conducted in Israel to estimate the incidence of CP, and the high CP prevalence documented is in agreement with previous reports from Europe and the USA. It also reaffirms the widespread existence of multifocal or widespread pain in clinical chronic pain and the correlation between pain intensity, impact on patients’ quality of life and disability, and pain intractability. These data reaffirm the similarly major health burden CP presents across different countries and cultures.

The aim of this study was to assess patient perspectives and experiences of the impact of neuropathic pain, painful diabetic neuropathy (pDPN) diagnosis and treatment, and the patient–healthcare professional (HCP) relationship. We conducted a quantitative online survey in Germany, the Netherlands, Spain, and the UK among adults with diabetes who responded “yes” to at least four of ten questions of in the Douleur Neuropathique en 4 Questions (DN4) questionnaire. Of 3626 respondents, 576 met the eligibility criteria. Daily pain was rated as moderate or severe by 79 % of respondents. Most participants reported a negative impact of their pain on sleep (74 %), mood (71 %), exercise (69 %), concentration (64 %) and daily activities (62 %), and 75 % of those in employment had missed work because of their pain in the past year. Overall, 22 % of respondents avoided discussing pain with their HCP, 50 % had not received formal pDPN diagnosis, and 56 % had not used prescribed pain medications. Although two-thirds (67 %) of respondents reported feeling satisfied or very satisfied with treatment, 82 % of these patients still experienced daily moderate or severe pain. Neuropathic pain in people with diabetes affects daily life and remains underdiagnosed and undertreated in clinical practice. •This patient survey provides unique insights into the impact of pDPN in Europe.•Daily pain was rated as moderate or severe by 79% of respondents.•Sleep, mood, exercise, concentration, daily activities and quality of life are affected.•75% of those in employment had missed work because of their pain in the past year.•pDPN remains underdiagnosed and undertreated in clinical practice.

Purpose Neurosurgical ablative procedures, such as cordotomy and cingulotomy, are often considered irreversible and destructive but can provide an effective and individualized solution for cancer-related refractory pain, when all other approaches have been unsuccessful. This paper provides an in-depth exploration of a novel approach to managing refractory cancer pain. It involves an interdisciplinary team led by a neurosurgeon at a renowned national referral center. Methods a retrospective analysis of the medical records of all sequential patients who underwent their initial evaluation at our interdisciplinary refractory cancer pain clinic from February 2017 to January 2023. Results A total of 207 patients were examined in the clinic for a first visit during the study period. All patients were referred to the clinic due to severe pain that was deemed refractory by the referring physician. The mean age was 61 ± 12.3 years, with no significant sex difference ( P  = 0.58). The mean ECOG Performance Status score was 2.35. Conservative measures had not yet been exhausted in 28 patients (14%) and 9 patients were well controlled (4%). Neurosurgical ablative procedures were recommended for 151 (73%) of the patients. Sixty-six patients (32%) eventually underwent the procedure. 91 patients (44%) received a negative recommendation for surgery. Thirty-five patients (17%) were referred for further invasive procedures at the pain clinic. Conclusion An Interdisciplinary cooperation between palliative care specialists, pain specialists, and neurosurgeons ensures optimal patient selection and provides safe and effective neurosurgery for the treatment of refractory cancer-related pain.

Context Opioid use disorder (OUD) poses significant public health problems that have increased dramatically, resulting in high rates of morbidity and mortality. Objectives To minimize the risk of an opioid epidemic in Israel and be prepared, we evaluated physicians’ objective knowledge, level of stigma, and approach to prescribing opioids, risk factors, and identification of patients with substance use disorder (SUD), as well as their knowledge about opioid maintenance treatment (OMT) for OUD. Methods Anonymous computerized questionnaires were distributed nationally to physicians by the Israel Medical Association. Knowledge, stigma, and approach were scored. Results Of only 249 responders, 58.6% prescribe opioids, 32.1% prescribe cannabis, and 18.5% daily encounter patients with SUD. Logistic regression found the high knowledge group had daily encounters with SUD (Odds Ratio (OR) = 3.5, 95% CI 1.7–7.1) and were familiar with OMT (OR = 10.1, 95% CI 3.5–29.0). The high stigma group was characterized by physicians who prescribe opioids (OR = 1.7, 95% CI 1.0–2.9), but who self-reported having limited knowledge regarding OMT (OR = 2, 95% CI 1.1–3.7). The high approach group was characterized by those who prescribe opioids (OR = 11.7, 95% CI 4.9–28), prescribe cannabis (OR = 2.1, 95% CI 1.0–4.3), self-report having limited knowledge regarding OMT (OR = 11.2, 95% CI 1.4–89) and self-report identifying SUD (OR = 32.5, 95% CI 4.1–260). Conclusion High stigma was most evident among physicians who prescribe opioids but, importantly, who had limited knowledge specifically regarding OMT. Gaps in knowledge and approach were observed. An educational intervention is highly recommended to reduce stigma and increase referrals of patients for OMT, the most effective treatment for opioid use disorder .

While advanced medical technology and unlimited access to medical information might benefit and empower patients, these same advantages may pose some risks, especially in the cases where patients have direct access to advanced imaging studies. The aim of this work was to evaluate three domains related to patients with lower back pain: the patients' perceptions, misconceptions and the experience of anxiety-related symptoms following direct access to their thoraco-lumbar spine radiology report. An additional aim was the assessment of possible associations with catastrophization. Patients who were referred to the spine clinic, following the completion of a CT or MRI of their thoraco-lumbar spine were surveyed. Patient perceptions of the importance of having direct access to their imaging report and of the concern they attribute to the medical terms found in their report were evaluated using a set of questionnaires. The medical terms severity scores were then correlated to a reference clinical score created for the same medical terms by spine surgeons. Lastly, patients' anxiety-related symptoms and Pain Catastrophizing Scale (PCS) after reading their radiology report were evaluated. Data from 162 participants (44.6% female), with mean age of 53.1 ± 15.6 years, were collected. Sixty-three percent of the patients stated that reading their report helped them gain better understanding of their medical condition and 84% agreed that having early access to the report helped improve communication with the physician. Patients' degree of concern associated with the medical terms in their imaging report ranged between 2.07 and 3.75, on a scale of 1-5. The patient's degree of concerns were significantly higher for six common medical terms and significantly lower in one, when compared to experts' opinions. A mean (± SD) of 2.86±2.79 anxiety-related symptoms was reported. The mean Pain Catastrophizing Scale (PSC) score was 29.18 ±11.86, ranging from 2 to 52. Both the degree of concerns and the number of symptoms reported were significantly associated with the PCS. Direct access to radiology reports might provoke anxiety symptoms, especially in patients with a tendency for catastrophic thinking. Increasing awareness amongst spine clinicians and radiologist about possible risks associated with direct access to radiology reports could contribute to preventing patients' misconceptions and unnecessary anxiety-related symptoms.

According to the Israeli Ministry of Health, more than 10 000 patients with cancer receive permits annually, making it the most commonly prescribed medication by the Israeli oncologists. [...]Israeli oncologists are unique in terms of their vast expertise in the use of cannabis for cancer-associated symptoms.3,4 To examine the experience, perceptions, and attitudes of Israeli oncologists towards the use of cannabis, we did a national web-based survey among all those oncologists who are registered with the Israeli Society of Clinical Oncology and Radiation Therapy. 126 (53%) of 238 registered oncologists responded to the survey. Importantly, pattern of use was affected by personal views. [...]although physicians favouring legalisation (n=46) and opposing legalisation (n=78) had similar views regarding indications, contraindications, activity, safety, and knowledge, those favouring legalisation reported recommending more permits per year than those opposing it (p=0·045; table). Because the use of cannabis for such purpose is not allowed, according to the Israeli Ministry of Health guidelines, and is not reported to oncologists, the magnitude of the phenomenon could not be assessed in this survey. Since no prospective clinical data regarding the efficacy of cannabis for cancer-related symptoms are available, the knowledge of oncologists who are experienced in its use is highly valuable.

Background Disordered autonomic nervous system regulation and supraspinal pain inhibition have been repeatedly described in chronic pain. We aimed to explore the effects of δ-9-tetrahydrocannabinol (THC), an emerging treatment option, on autonomic nervous system and central pain modulation measures in patients with chronic pain. Methods Twelve male patients with chronic radicular neuropathic pain participated in a randomized, double-blind, crossover, placebo-controlled, single-administration trial. Low/high frequency (LF/HF) heart rate variability (HRV) ratio and conditioned pain modulation (CPM) response were measured and resting-state functional magnetic resonance imaging (MRI) was performed at baseline and after sublingual administration of either 0.2 mg/kg oral THC or placebo. Results THC significantly reduced the LF/HF ratio compared with placebo (interaction effect F (1,11) = 20.5; p  < 0.005) and significantly improved CPM responses (interaction effect F (1,9) = 5.2; p  = 0.048). The THC-induced reduction in LF/HF ratio correlated with increased functional connectivity between the rostral ventrolateral medulla and the dorsolateral prefrontal cortex [T(10) = 6.4, cluster p -FDR < 0.005]. Conclusions THC shifts the autonomic balance towards increased parasympathetic tone and improves inhibitory pain mechanisms in chronic pain. The increase in vagal tone correlates with connectivity changes in higher-order regulatory brain regions, suggesting THC exerts top-down effects. These changes may reflect a normalizing effect of THC on multiple domains of supraspinal pain dysregulation. Clinical Trial Registry Number NCT02560545.

Background and objectivesCancer-related pain management in advanced stages presents a significant challenge that often requires a multidisciplinary approach. Although advancements in pharmacological and interventional therapies, a considerable number of patients still suffer from refractory pain, leading to unmet clinical needs. This study shares our experience with medical cannabis (MC) as a potential therapy for this specific population of patients with cancer-related refractory pain.MethodsIn a cross-sectional study, 252 consecutive refractory cancer-related pain patients (mean age=61.71, SD=14.02, 47.6% males) filled out detailed self-report questionnaires. Of these, 126 patients (55%) were treated with MC and 105 patients (45%) were not.ResultsMost patients received pain management from their oncologist, not a pain specialist. MC was mainly started for pain relief, sleep difficulties and anorexia. About 70% of patients reported subjective improvement from MC, with almost 40% reporting a significant improvement in coping with their illness. Side effects were generally mild, with fatigue and dizziness being the most common (21.78% and 23.46%, respectively). No patient required dedicated medical care for side effects. Of non-users, 65% had tried MC before and stopped due to lack of effectiveness or side effects (39.7% and 34.6%, respectively).ConclusionRefractory cancer pain necessitates innovative approaches. This registry highlights that MC can effectively improve symptoms in non-responsive patients, with favourable safety profiles for this vulnerable population.

We have evaluated randomized controlled trials of the administration of clonidine, neostigmine, steroids and non-steroidal anti-inflammatory agents intra-articularly as adjuvants to local anesthetic drugs after arthroscopic knee surgery. Twenty-five studies were reviewed using specific inclusion criteria and, accordingly, included in the final assessment. These studies were assessed for pain scores, total analgesic consumption and time to first analgesic request to determine a possible peripheral effect, as opposed to possible systemic effects of an adjuvant administered intra-articularly. A total of 16 studies, met the inclusion criteria. These studies considered the use of non-steroidal anti-inflammatory drugs, steroids, neostigmine and clonidine. Ketorolac was used in four studies (for a total of 230 patients) and showed a significant improvement in analgesia. Clonidine has shown considerable analgesic effect, with minimal adverse effects. All seven studies assessed in this review were supportive (a total of 424 patients). Furthermore the addition of clonidine to bupivacaine or morphine was found to increase duration and quality of postoperative analgesia. Current evidence indicates that a variety of agents have synergistic effects when added to local anesthetics and there is evidence that the improvement in analgesia is, at least partially, through a local rather than a central mechanism. The results of this review suggest that clonidine and ketorolac, when administered intra-articulary after arthroscopic knee surgery, may reduce postoperative pain.